Physician profile
Azeem Khan
NPI 1538183678
$13,534.03
in general payments reported to CMS, 2019-2025
41 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $1,048 · 2021: $1,810 · 2022: $828 · 2023: $1,603 · 2024: $6,267 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $6,249 · Food and Beverage: $2,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $6,248.75 |
| Food and Beverage | $2,393.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,248.75 | 2023-2024 | |
| Abbvie INC. | $3,517.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $646.13 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $521.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.08 | 2019-2022 | |
| Intra-Sana Laboratories | $272.27 | 2021-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Biotech, INC. | $242.80 | 2021-2025 | Tremfya, Stelara |
| Celgene Corporation | $187.82 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $128.37 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Zeposia |
| Allergan, INC. | $124.99 | 2019 | |
| Ironwood Pharmaceuticals, INC | $121.40 | 2019-2021 | |
| Amgen INC. | $112.39 | 2020-2021 | |
| Genzyme Corporation | $104.18 | 2021-2025 | |
| Braintree Laboratories, INC. | $101.56 | 2019-2024 | Sutab, Suflave |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeem Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.